公开(公告)号：US20150152186A1

公开(公告)日：2015-06-04

申请号：US14553669

申请日：2014-11-25

Applicant: BioNTech AG

Inventor： Klaus Pfizenmaier ,  Harald Wajant ,  Dieter Moosmayer ,  Thomas Wuest

IPC: C07K16/28 ,  C07K14/705 ,  C07K14/525

CPC classification number: C07K16/2866 ,  A61K47/6899 ,  B82Y5/00 ,  C07K14/525 ,  C07K14/70575 ,  C07K2319/00

Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.

Abstract translation: 本发明的主题是具有促细胞凋亡和免疫调节性质的抗体 - 细胞因子融合蛋白，但是其中先前的细胞因子部分具有非常低的或限于某些受体亚型的生物活性。 这些试剂只有在融合蛋白与特异性细胞膜表达的靶分子的抗体介导的结合之后才通过相应的细胞因子受体发挥其完整的生物活性。 通过适当选择抗体特异性，将细胞因子活性导向组织，例如， 可以对各种适应症/肿瘤实体进行特异性设计/优化来制备待治疗的肿瘤组织和治疗剂。

公开(公告)号：US09944708B2

公开(公告)日：2018-04-17

申请号：US14553669

申请日：2014-11-25

Applicant: BioNTech AG

Inventor： Klaus Pfizenmaier ,  Harald Wajant ,  Dieter Moosmayer ,  Thomas Wuest

IPC: C07K19/00 ,  A61K47/42 ,  A61K38/19 ,  C07K16/28 ,  B82Y5/00 ,  C07K14/525 ,  C07K14/705 ,  A61K47/68 ,  C07K16/30 ,  C07K14/715 ,  C07K7/04 ,  C07K7/06 ,  C07K7/08

CPC classification number: C07K16/2866 ,  A61K47/6899 ,  B82Y5/00 ,  C07K14/525 ,  C07K14/70575 ,  C07K2319/00

Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.